SGLT2 Inhibitors and GLP-1 Receptor Agonists
Cross-source consensus on SGLT2 Inhibitors and GLP-1 Receptor Agonists from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Comparisons
Background
Evidence quality
Highlighted claims
- Large cardiovascular outcome trials show that both drug classes independently reduce cardiovascular events in patients with established CVD or very high risk. — Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?
- Their role in primary cardiovascular prevention and the additive effect of combining them remain unsettled. — Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?
- SGLT2 inhibitors and GLP-1 receptor agonists have changed the therapeutic landscape for cardiovascular risk management in diabetes. — Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?
- In Danish baseline screening data, SGLT2i and GLP1ra use was similar regardless of CAC score. — Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?